Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity

Fig. 5

PK5-RL-Gal-3C inhibits HCC cell proliferation in vitro. HCC cells were respectively treated with rPK5, rGal-3C, and rPK5-RL-Gal-3C under the indicated concentrations (0, 1, 2, 3 and 4 μmol/l) for 48 h, and then analyzed with a MTT assay kit. A rPK5-RL-Gal-3C treatment inhibited cell proliferation of HepG2, Huh7, and PLC/PRF/5. B rPK5-RL-Gal-3C exhibited stronger inhibitory action than combination of rPK5 and rGal-3C to PLC/PRF/5 cells. C Lactose not sucrose could suppress the inhibitory effect of rPK5-RL-Gal-3C to PLC/PRF/5 cells. Significant differences are denoted by ** for p < 0.01, *** for p < 0.001, and ns, no significance

Back to article page